Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
2013; American Association for Cancer Research; Volume: 19; Issue: 19 Linguagem: Inglês
10.1158/1078-0432.ccr-13-1262
ISSN1557-3265
AutoresJoo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira‐Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-may Chen, Michael Friedlander, Bella Kaufman, Amit M. Oza, Ursula A. Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James Campbell, Lina Chen, Johann S. de Bono, Martin Gore, Christopher J. Lord, Alan Ashworth, Stan B. Kaye,
Tópico(s)Ovarian cancer diagnosis and treatment
ResumoPreclinical data suggest that exposure to PARP inhibitors (PARPi) may compromise benefit to subsequent chemotherapy, particularly platinum-based regimens, in patients with BRCA1/2 mutation carrier ovarian cancer (PBMCOC), possibly through the acquisition of secondary BRCA1/2 mutations. The efficacy of chemotherapy in the PARPi-resistant setting was therefore investigated.
Referência(s)